Meda has announced an expansion in its partnership with Cipla, which is already supplying azelastine for Meda’s Dymista nasal spray. With the new agreement, Meda will continue to take responsibility for clinical development and commercialization of Dymista; Cipla will take responsibility for formulation. According to Meda, the company will “now have full coverage in all growth markets in Latin- and South America, Middle East and Africa and Asia, including more than 120 new markets.”
Dymista was approved for the treatment of allergic rhinitis in the US in May 2012. The EU approved Dymista at the beginning of this year.
Meda CEO Anders Lönner commented, “Through this expanded partnership, we secure opportunities for global commercialization of Dymista and optimize future product development. Not least, we see great potential in several priority growth markets such as China.”
The company also released a “comment on speculation in the media,” denying that it is involved in any merger discussions. Reuters had reported that Sun Pharmaceuticals was in talks to buy Meda for $5-6 billion.
Read the Meda press release on the Cipla partnership.
